Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company dedicated to developing, manufacturing, and distributing a diverse portfolio of generic and specialty pharmaceutical products. Headquartered in Bridgewater, New Jersey, the company operates with a mission to make healthy possible by providing high-quality, accessible, and affordable medicines to patients.

The company's operations are segmented into Generics, Specialty, and Biosimilars. Its Generics division offers a broad range of products across various therapeutic areas, including complex oral solids, injectables, ophthalmics, and transdermals. The Specialty division focuses on branded pharmaceuticals for Central Nervous System disorders, such as Parkinson's disease and migraines, and Endocrine disorders, including hypothyroidism, with key products like Rytary®, Crexont®, Unithroid®, and Emverm®. Amneal is also building a significant presence in biosimilars, particularly in oncology and movement disorders, and distributes pharmaceuticals to the U.S. federal government, retail, and institutional markets through its AvKARE segment.

Led by Co-CEOs and Co-Founders Chirag Patel and Chintu Patel, Amneal Pharmaceuticals is a publicly traded entity on the NASDAQ under the ticker AMRX. In April 2026, the company announced plans to acquire Kashiv BioSciences in a $750 million deal, aiming to establish itself as a global biosimilar leader and accelerate its pipeline in this segment. This strategic move, alongside strong preliminary Q1 2026 financial results and raised full-year guidance, underscores Amneal's commitment to growth and diversification within the pharmaceutical market. The company was also added to the S&P SmallCap 600® Index in January 2026.